Aytu BioPharma Inc
AYTU
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.36M
Close$
$-1.88
194.3% downside
Current Fair Value
194.3% downsideOvervalued by 194.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $21.36 Million |
|---|---|
| Enterprise Value | $6.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.16 |
| Beta | 0.27 |
| Outstanding Shares | 10,511,583 |
Return
| Return on Equity | -96.90% |
|---|---|
| Return on Assets | -30.49% |
| Return on Invested Capital | -48.94% |
Valuation & Multiples
| P/E Ratio | -0.46 |
|---|---|
| PEG | 0.19 |
| Price to Sales | 0.4 |
| Price to Book Ratio | 0.66 |
| Enterprise Value to Revenue | 0.12 |
| Enterprise Value to EBIT | -0.28 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.77 |
| Debt to Equity | 0.35 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$13.29 M
Average shareholder expectationNext Earnings Call
Expected Date
September 22, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$12.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.49%▼ 1.11% |
|---|---|
| Total Invested | $8.25M▼ 43.67% |
| Investors Holding | 36▲ 1.00% |
ESG Score
No data
About Aytu BioPharma Inc
75 employees